Compared with other systemic agents for treating atopic dermatitis, dupilumab is associated with an increased risk for ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

PORTLAND, OR, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- The global atopic dermatitis market is witnessing unprecedented growth, projected to expand from $5.3 billion in 2021 to $22.6 billion ...

Paris: Sanofi has successfully priced its offering of euro 1.5 billion of notes across 2 tranches:€750 million fixed-rate ...

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Greater disease control and satisfaction as well as lower recurrence rates were associated with isotretinoin 20 mg vs 10 mg for seborrheic dermatitis.

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Nektar Therapeutics' REZPEG shows progress in treating atopic dermatitis & alopecia areata. Click here to find out why I rate ...

aDepartment of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China bInnovation Center for Medical Basic ...

Sanofi presents positive results from DISCOVER phase 4 study of Dupixent in atopic dermatitis patients with skin of colour at 2025 RAD conference: Paris Tuesday, June 10, 2025, 16 ...